However, another study addressing tocilizumab treatment of RA patients found significantly higher adiponectin levels in RA at baseline, while after tocilizumab treatment, resistin levels and the leptin–adiponectin ratio were increased; in contrast, BMI-adjusted adiponectin levels were decreased and leptin levels remained unchanged [78]. This evidence concerns the gene ADIPOQ and rheumatoid arthritis.